Now Available

Easy to order

Nationwide Distribution

We are excited to announce that Ethiqa XR® is now available from MWI Animal Health and Covetrus. Contact MWI or Covetrus to place your order.

800-824-3703

Product Number 099114

855-724-3461

Product Number FP-001 #072117

Ethiqa XR should be handled carefully to minimize the risk of diversion, including restriction of access, the use of accounting procedures, and proper disposal methods, as appropriate to the laboratory setting and as required by law.

vial2

Ethiqa XR® Dosing and Specifications

Packaging Multi-dose 3 mL vials
Buprenorphine concentration 1.3 mg/mL
Dosing—Mice Single subcutaneous injection of 0.05 mL per 20-gram mouse (3.25 mg/kg body weight)
Dosing—Rats Single subcutaneous injection of 0.1 mL per 200-gram rat (0.65 mg/kg body weight)
Dose Repetition If needed, a single repeat dose may be administered after the initial dose
Syringe/Needle Size Use a 0.5- or 1.0-mL syringe fitted with a 20- to 23-gauge needle for injections
Stability Approved for 12-month shelf life
Storage Store vial at 15° to 25°C (59° to 77°F) or refrigerated. Do not freeze. Store in a locked, substantially constructed cabinet according to DEA and local controlled substance guidelines
Administration Ethiqa XR should only be handled and administered by a veterinarian, veterinary technician or laboratory staff trained in the handling of potent opioids

Boxed Warning

WARNING: ABUSE POTENTIAL and LIFE-THREATENING RESPIRATORY DEPRESSION and ACCIDENTAL EXPOSURE

Abuse Potential

Ethiqa XR contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of Ethiqa XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.

Do not dispense Ethiqa XR.

Life-Threatening Respiratory Depression

The concentration of buprenorphine in Ethiqa XR is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of Ethiqa XR. Ethiqa XR has additive CNS depressant effects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids.

Important Safety Information for Rats and Mice, Not for use in humans

For Rats and Mice:

Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression.

For Humans:

Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans. 

For more information, consult the prescribing information including the boxed warning.